{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T16:45:18Z","timestamp":1792255518342,"version":"4.4.0"},"reference-count":60,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T00:00:00Z","timestamp":1757289600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012543","name":"Shanghai Science and Technology Development Foundation","doi-asserted-by":"publisher","award":["24YF275530"],"award-info":[{"award-number":["24YF275530"]}],"id":[{"id":"10.13039\/100012543","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["92253306"],"award-info":[{"award-number":["92253306"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82273951"],"award-info":[{"award-number":["82273951"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82173660"],"award-info":[{"award-number":["82173660"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82404655"],"award-info":[{"award-number":["82404655"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010031","name":"Postdoctoral Research Foundation of China","doi-asserted-by":"publisher","award":["2024M750708"],"award-info":[{"award-number":["2024M750708"]}],"id":[{"id":"10.13039\/501100010031","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Pharmaceutica Sinica B"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.apsb.2025.09.009","type":"journal-article","created":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T07:04:47Z","timestamp":1757660687000},"page":"6510-6528","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Rational engineering of degradation tail-driven CELMoD\u2013antibody conjugates for precision malignancy therapy"],"prefix":"10.1016","volume":"15","author":[{"given":"Yu","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanlin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheyuan","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weijuan","family":"Kan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiting","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuangshuang","family":"Geng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoting","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bizhi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanshan","family":"Pei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luo","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yubo","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinxin","family":"Che","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2178-4372","authenticated-orcid":false,"given":"Xiaowu","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.apsb.2025.09.009_bib1","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/S0140-6736(21)00135-5","article-title":"Multiple myeloma","volume":"397","author":"van de Donk","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.apsb.2025.09.009_bib2","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41572-024-00529-7","article-title":"Multiple myeloma","volume":"10","author":"Malard","year":"2024","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.apsb.2025.09.009_bib3","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.apsb.2025.09.009_bib4","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.apsb.2025.09.009_bib5","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/joim.12590","article-title":"Modern multiple myeloma therapy: deep, sustained treatment response and good clinical outcomes","volume":"281","author":"Landgren","year":"2017","journal-title":"J Intern Med"},{"key":"10.1016\/j.apsb.2025.09.009_bib6","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","article-title":"Daratumumab plus lenalidomide and dexamethasone for untreated myeloma","volume":"380","author":"Facon","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.apsb.2025.09.009_bib7","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1200\/JCO.2017.72.6679","article-title":"Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis","volume":"35","author":"McCarthy","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.apsb.2025.09.009_bib8","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.chembiol.2021.04.012","article-title":"Exploiting ubiquitin ligase cereblon as a target for small-molecule compounds in medicine and chemical biology","volume":"28","author":"Ito","year":"2021","journal-title":"Cell Chem Biol"},{"key":"10.1016\/j.apsb.2025.09.009_bib9","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1021\/acs.jmedchem.6b01921","article-title":"A cereblon modulator (CC-220) with improved degradation of Ikaros and Aiolos","volume":"61","author":"Matyskiela","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2025.09.009_bib10","doi-asserted-by":"crossref","first-page":"6648","DOI":"10.1021\/acs.jmedchem.9b01928","article-title":"Discovery of CRBN E3 ligase modulator CC-92480 for the treatment of relapsed and refractory multiple myeloma","volume":"63","author":"Hansen","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2025.09.009_bib11","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1056\/NEJMoa2303194","article-title":"Mezigdomide plus dexamethasone in relapsed and refractory multiple myeloma","volume":"389","author":"Richardson","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.apsb.2025.09.009_bib12","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1146\/annurev-med-112017-091045","article-title":"New drugs in multiple myeloma","volume":"70","author":"Kunacheewa","year":"2019","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.apsb.2025.09.009_bib13","doi-asserted-by":"crossref","first-page":"D1097","DOI":"10.1093\/nar\/gkad831","article-title":"ADCdb: the database of antibody\u2013drug conjugates","volume":"52","author":"Shen","year":"2024","journal-title":"Nucleic Acids Res"},{"issue":"Suppl 2","key":"10.1016\/j.apsb.2025.09.009_bib14","first-page":"S22","article-title":"Antibody drug conjugates for the treatment of multiple myeloma","volume":"98","author":"Leong","year":"2023","journal-title":"Am J Hematol"},{"key":"10.1016\/j.apsb.2025.09.009_bib15","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1182\/blood-2013-10-535088","article-title":"Novel anti-B-cell maturation antigen antibody\u2013drug conjugate (GSK2857916) selectively induces killing of multiple myeloma","volume":"123","author":"Tai","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.apsb.2025.09.009_bib16","doi-asserted-by":"crossref","first-page":"4629","DOI":"10.1158\/1078-0432.CCR-22-0618","article-title":"FDA approval summary: belantamab mafodotin for patients with relapsed or refractory multiple myeloma","volume":"28","author":"Baines","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.apsb.2025.09.009_bib17","doi-asserted-by":"crossref","first-page":"e801","DOI":"10.1016\/S2352-3026(23)00243-0","article-title":"Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study","volume":"10","author":"Dimopoulos","year":"2023","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.apsb.2025.09.009_bib18","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMoa2405090","article-title":"Belantamab mafodotin, bortezomib, and dexamethasone for multiple myeloma","volume":"391","author":"Hungria","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.apsb.2025.09.009_bib19","article-title":"Results from the randomized phase III DREAMM-7 study of belantamab mafodotin (belamaf) + bortezomib, and dexamethasone (BVd) vs daratumumab, bortezomib, and dexamethasone (DVd) in relapsed\/refractory multiple myeloma (RRMM)","volume":"42","author":"Mateos","year":"2024","journal-title":"J Clin Orthod"},{"key":"10.1016\/j.apsb.2025.09.009_bib20","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1182\/blood-2020-136375","article-title":"Phase 1, first-in-human study of MEDI2228, a BCMA-targeted ADC in patients with relapsed\/refractory multiple myeloma","volume":"136","author":"Kumar","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.apsb.2025.09.009_bib21","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/s41375-020-0834-9","article-title":"Phase 1 study of the anti-BCMA antibody\u2013drug conjugate AMG 224 in patients with relapsed\/refractory multiple myeloma","volume":"35","author":"Lee","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.apsb.2025.09.009_bib22","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1158\/1078-0432.CCR-19-1431","article-title":"First-in-human Phase I study of ABBV-838, an antibody\u2013drug conjugate targeting SLAMF7\/CS1 in patients with relapsed and refractory multiple myeloma","volume":"26","author":"Vij","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.apsb.2025.09.009_bib23","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.clml.2018.08.018","article-title":"A Phase I study to assess the safety and pharmacokinetics of single-agent lorvotuzumab mertansine (IMGN901) in patients with relapsed and\/or refractory CD-56-positive multiple myeloma","volume":"19","author":"Ailawadhi","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.apsb.2025.09.009_bib24","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1182\/blood.V55.3.364.364","article-title":"Pretreatment tumor mass, cell kinetics, and prognosis in multiple myeloma","volume":"55","author":"Durie","year":"1980","journal-title":"Blood"},{"key":"10.1016\/j.apsb.2025.09.009_bib25","doi-asserted-by":"crossref","first-page":"6333","DOI":"10.1200\/JCO.2005.05.021","article-title":"Molecular pathogenesis and a consequent classification of multiple myeloma","volume":"23","author":"Bergsagel","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.apsb.2025.09.009_bib26","doi-asserted-by":"crossref","first-page":"3886","DOI":"10.1039\/D2CS00141A","article-title":"Degrader\u2013antibody conjugates","volume":"51","author":"Dragovich","year":"2022","journal-title":"Chem Soc Rev"},{"key":"10.1016\/j.apsb.2025.09.009_bib27","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1021\/acs.jmedchem.2c01791","article-title":"Degrader\u2013antibody conjugates: emerging new modality","volume":"66","author":"Hong","year":"2023","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2025.09.009_bib28","doi-asserted-by":"crossref","first-page":"5498","DOI":"10.1039\/D2CS00197G","article-title":"Chasing molecular glue degraders: screening approaches","volume":"51","author":"Domostegui","year":"2022","journal-title":"Chem Soc Rev"},{"key":"10.1016\/j.apsb.2025.09.009_bib29","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.cell.2019.11.031","article-title":"Proteolysis-targeting chimeras as therapeutics and tools for biological discovery","volume":"181","author":"Burslem","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.apsb.2025.09.009_bib30","doi-asserted-by":"crossref","first-page":"5740","DOI":"10.1039\/D2CS00200K","article-title":"Target and tissue selectivity of PROTAC degraders","volume":"51","author":"Guenette","year":"2022","journal-title":"Chem Soc Rev"},{"key":"10.1016\/j.apsb.2025.09.009_bib31","doi-asserted-by":"crossref","first-page":"8428","DOI":"10.1021\/acs.jmedchem.3c00302","article-title":"Recent advances in pro-PROTAC development to address on-target off-tumor toxicity","volume":"66","author":"Chen","year":"2023","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2025.09.009_bib32","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1021\/acs.bioconjchem.4c00124","article-title":"Welding PROxAb shuttles: a modular approach for generating bispecific antibodies via site-specific protein\u2013protein conjugation","volume":"35","author":"Lehmann","year":"2024","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.apsb.2025.09.009_bib33","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1038\/s41467-024-46167-1","article-title":"Delivery of a BET protein degrader via a CEACAM6-targeted antibody\u2013drug conjugate inhibits tumour growth in pancreatic cancer models","volume":"15","author":"Nakazawa","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2025.09.009_bib34","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1021\/acs.jmedchem.0c01845","article-title":"Antibody-mediated delivery of chimeric BRD4 degraders. Part 1: exploration of antibody linker, payload loading, and payload molecular properties","volume":"64","author":"Dragovich","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2025.09.009_bib35","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1021\/acs.jmedchem.0c01846","article-title":"Antibody-mediated delivery of chimeric BRD4 degraders. Part 2: improvement of in vitro antiproliferation activity and in vivo antitumor efficacy","volume":"64","author":"Dragovich","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2025.09.009_bib36","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1021\/acs.bioconjchem.3c00535","article-title":"Design, synthesis, and in vitro and in vivo evaluation of cereblon binding Bruton\u2019s tyrosine kinase (BTK) degrader CD79b targeted antibody\u2013drug conjugates","volume":"35","author":"Zhang","year":"2024","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.apsb.2025.09.009_bib37","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1021\/acs.bioconjchem.3c00366","article-title":"Antibody-proteolysis targeting chimera conjugate enables selective degradation of receptor-interacting serine\/threonine-protein kinase 2 in HER2+ cell lines","volume":"34","author":"Chan","year":"2023","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.apsb.2025.09.009_bib38","article-title":"A phase 1, first-in-human, open label, escalation and expansion study of ORM-5029, a highly potent GSPT1 degrader targeting HER2, in patients with HER2-expressing advanced solid tumors","volume":"41","author":"Hurvitz","year":"2023","journal-title":"J Clin Orthod"},{"key":"10.1016\/j.apsb.2025.09.009_bib39","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1182\/blood-2022-168936","article-title":"ORM-6151: a first-in-class, anti-CD33 antibody-enabled GSPT1 degrader for AML","volume":"140","author":"Palacino","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.apsb.2025.09.009_bib40","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1158\/1538-7445.AM2023-2700","article-title":"Abstract 2700: ORM-6151: a first-in-class CD33-antibody enabled GSPT1 degrader for AML","volume":"83","author":"Palacino","year":"2023","journal-title":"Cancer Res"},{"key":"10.1016\/j.apsb.2025.09.009_bib41","doi-asserted-by":"crossref","first-page":"3933","DOI":"10.1158\/1538-7445.AM2022-3933","article-title":"Abstract 3933: ORM-5029: a first-in-class targeted protein degradation therapy using antibody neodegrader conjugate (AnDC) for HER2-expressing breast cancer","volume":"82","author":"Palacino","year":"2022","journal-title":"Cancer Res"},{"key":"10.1016\/j.apsb.2025.09.009_bib42","article-title":"An antibody\u2013drug conjugate for multiple myeloma prepared by multi-arm linkers","volume":"11","author":"Yu","year":"2024","journal-title":"Adv Sci (Weinh)"},{"key":"10.1016\/j.apsb.2025.09.009_bib43","doi-asserted-by":"crossref","first-page":"15996","DOI":"10.1021\/acs.jmedchem.4c01289","article-title":"The new frontier: merging molecular glue degrader and antibody\u2013drug conjugate modalities to overcome strategic challenges","volume":"67","author":"Poudel","year":"2024","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2025.09.009_bib44","doi-asserted-by":"crossref","first-page":"10606","DOI":"10.1021\/acs.jmedchem.1c00895","article-title":"Molecular glues for targeted protein degradation: from serendipity to rational discovery","volume":"64","author":"Dong","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2025.09.009_bib45","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1021\/acs.biochem.2c00245","article-title":"Molecular glues: the adhesive connecting targeted protein degradation to the clinic","volume":"62","author":"Sasso","year":"2023","journal-title":"Biochemistry"},{"key":"10.1016\/j.apsb.2025.09.009_bib46","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.chembiol.2024.04.002","article-title":"Molecular glues for protein\u2013protein interactions: Progressing toward a new dream","volume":"31","author":"Konstantinidou","year":"2024","journal-title":"Cell Chem Biol"},{"key":"10.1016\/j.apsb.2025.09.009_bib47","doi-asserted-by":"crossref","DOI":"10.1126\/science.aat0572","article-title":"Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN","volume":"362","author":"Sievers","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.apsb.2025.09.009_bib48","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/s41557-023-01379-8","article-title":"Proteolysis-targeting chimeras with reduced off-targets","volume":"16","author":"Nguyen","year":"2023","journal-title":"Nat Chem"},{"key":"10.1016\/j.apsb.2025.09.009_bib49","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202402267","article-title":"Unlocking amides: a general method for the self-immolative release of amide-containing molecules","volume":"63","author":"Wharton","year":"2024","journal-title":"Angew Chem Int Ed"},{"key":"10.1016\/j.apsb.2025.09.009_bib50","doi-asserted-by":"crossref","first-page":"4683","DOI":"10.1038\/s41467-023-40385-9","article-title":"Lenalidomide derivatives and proteolysis-targeting chimeras for controlling neosubstrate degradation","volume":"14","author":"Yamanaka","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2025.09.009_bib51","article-title":"Rational identification of novel antibody\u2013drug conjugate with high bystander killing effect against heterogeneous tumors","volume":"11","author":"Guo","year":"2024","journal-title":"Adv Sci (Weinh)"},{"key":"10.1016\/j.apsb.2025.09.009_bib52","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1158\/2159-8290.CD-22-1368","article-title":"Antibody\u2013exatecan conjugates with a novel self-immolative moiety overcome resistance in colon and lung cancer","volume":"13","author":"Weng","year":"2023","journal-title":"Cancer Discov"},{"key":"10.1016\/j.apsb.2025.09.009_bib53","doi-asserted-by":"crossref","first-page":"19852","DOI":"10.1021\/acs.jmedchem.4c02243","article-title":"Evaluation of double self-immolative linker-based antibody\u2013drug conjugate FDA022-BB05 with enhanced therapeutic potential","volume":"67","author":"Zhang","year":"2024","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2025.09.009_bib54","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-018-04982-3","article-title":"Glutamic acid\u2013valine\u2013citrulline linkers ensure stability and efficacy of antibody\u2013drug conjugates in mice","volume":"9","author":"Anami","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2025.09.009_bib55","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1182\/blood-2018-05-850727","article-title":"IMiDs prime myeloma cells for daratumumab-mediated cytotoxicity through loss of Ikaros and Aiolos","volume":"132","author":"Fedele","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.apsb.2025.09.009_bib56","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/nature07064","article-title":"IRF4 addiction in multiple myeloma","volume":"454","author":"Shaffer","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2025.09.009_bib57","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1038\/onc.2015.245","article-title":"Immunomodulatory drugs target IKZF1-IRF4-MYC axis in primary effusion lymphoma in a cereblon-dependent manner and display synergistic cytotoxicity with BRD4 inhibitors","volume":"35","author":"Gopalakrishnan","year":"2016","journal-title":"Oncogene"},{"key":"10.1016\/j.apsb.2025.09.009_bib58","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.apsb.2025.09.009_bib59","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1126\/science.1244851","article-title":"Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells","volume":"343","author":"Kr\u00f6nke","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.apsb.2025.09.009_bib60","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1182\/blood-2015-07-567958","article-title":"The novel mechanism of lenalidomide activity","volume":"126","author":"Fink","year":"2015","journal-title":"Blood"}],"container-title":["Acta Pharmaceutica Sinica B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383525006069?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383525006069?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T08:37:43Z","timestamp":1777624663000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211383525006069"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":60,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S2211383525006069"],"URL":"https:\/\/doi.org\/10.1016\/j.apsb.2025.09.009","relation":{},"ISSN":["2211-3835"],"issn-type":[{"value":"2211-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rational engineering of degradation tail-driven CELMoD\u2013antibody conjugates for precision malignancy therapy","name":"articletitle","label":"Article Title"},{"value":"Acta Pharmaceutica Sinica B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.apsb.2025.09.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V. on behalf of Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences.","name":"copyright","label":"Copyright"}]}}